Crescent Biopharma, Inc. - Asset Resilience Ratio
Crescent Biopharma, Inc. (CBIO) has an Asset Resilience Ratio of 0.01% as of March 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CBIO working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2016)
This chart shows how Crescent Biopharma, Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Crescent Biopharma, Inc.'s balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Crescent Biopharma, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Crescent Biopharma, Inc. total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.22K | 0.01% |
| Total Liquid Assets | $5.22K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Crescent Biopharma, Inc. maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Crescent Biopharma, Inc. Industry Peers by Asset Resilience Ratio
Compare Crescent Biopharma, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Crescent Biopharma, Inc. (2011–2016)
The table below shows the annual Asset Resilience Ratio data for Crescent Biopharma, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 0.03% | $10.65K | $42.39 Million | +0.01pp |
| 2015-12-31 | 0.02% | $9.27K | $48.46 Million | -0.01pp |
| 2014-12-31 | 0.03% | $16.29K | $57.26 Million | +0.01pp |
| 2013-12-31 | 0.02% | $1.00K | $5.28 Million | -94.30pp |
| 2012-12-31 | 94.32% | $17.37 Million | $18.42 Million | -3.13pp |
| 2011-12-31 | 97.45% | $28.17 Million | $28.91 Million | -- |
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the develo… Read more